$SYF is a publicly traded company in the Finance sector. This company operates across Finance and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 3 active Congressional signals mentioning $SYF, including 3 bills. The current legislative sentiment leans bearish, with regulatory or policy headwinds potentially affecting performance.
The Bankruptcy Threshold Adjustment Act of 2026, reported out of committee and awaiting floor action, doubles the debt limits for consumer Chapter 13 and small business Chapter 11 filings. This directly expands credit loss severities for U.S. consumer lenders. Capital One ($COF), Synchrony ($SYF), and Ally Financial ($ALLY) face earnings headwinds of 8–30% from higher charge-off rates. Citigroup ($C) faces moderate incremental losses. The 30-day uptrend in lender stocks risks reversal as the bill's passage probability increases.
→ A wider Chapter 13 eligibility net captures more of Synchrony's customer base that default but previously exceeded the old debt threshold. The affected cohort generates 20–30% higher loss severities upon bankruptcy filing due to Synchrony's thin credit file underwriting.
S.3281 is an early-stage bill to repeal the nutrition title changes from the 2023 farm bill, restoring prior SNAP eligibility rules. It has been referred to committee with no further action in 5 months. There is no explicit funding amount, no market-moving mechanism, and the bill faces a long legislative path with uncertain prospects. Market impact is negligible at this stage.
→ Restoration of prior SNAP eligibility rules reduces the total number of SNAP-eligible households by reinstating asset and net income tests that were eliminated by the 2023 farm bill provisions
The Buy Now, Pay Later Protection Act of 2025 (S.3561) introduces TILA compliance requirements for BNPL loans, directly increasing operating costs for Affirm ($AFRM) while benefiting established credit card issuers Capital One ($COF) and Synchrony ($SYF) who already comply. The bill is at early stage (referred to committee) with 4 cosponsors, making near-term passage uncertain but the regulatory direction is clear.
→ BNPL's regulatory-cost advantage over Synchrony's installment and card products is reduced, making Synchrony's existing products relatively more competitive at the point of sale. Synchrony issues private-label credit cards and CareCredit — direct competitors to BNPL in retail and healthcare verticals.